Inhibitors of c-jun-N-terminal kinase (JNK)

Mini Rev Med Chem. 2008 Jul;8(8):755-66. doi: 10.2174/138955708784912120.

Abstract

Inhibitors of c-jun-N-Terminal Kinase (JNK) have many potential therapeutic indications ranging from neurodegenerative disease, to metabolic disorders, inflammation, cardiovascular disease, and cancer. This overview will highlight biological inhibitors such as JNK-interacting protein (JIP) as well as small molecule inhibitors from various structural classes including, aminopyrimidines and indazoles.

MeSH terms

  • Animals
  • Humans
  • JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors*
  • JNK Mitogen-Activated Protein Kinases / metabolism
  • Protein Kinase Inhibitors / chemistry*
  • Protein Kinase Inhibitors / pharmacology*
  • Pyridines / chemistry
  • Pyridines / pharmacology
  • Quinolines / chemistry
  • Quinolines / pharmacology
  • Structure-Activity Relationship

Substances

  • Protein Kinase Inhibitors
  • Pyridines
  • Quinolines
  • quinoline
  • JNK Mitogen-Activated Protein Kinases
  • pyridine